IPM Take
This is where bladder-cancer policy becomes practical. Adding durvalumab to BCG is not simply adding a drug. It means longer treatment, more monitoring, more toxicity management, and more pressure on urology-oncology coordination. If health systems do not build capacity around the pathway, the best-resourced centres will benefit first and everyone else will wait.
Executive Summary
New oncology coverage of expanded POTOMAC analyses reports that durvalumab plus BCG induction and maintenance delayed high-risk events and improved cystectomy-free survival in BCG-naive, high-risk non–muscle-invasive bladder cancer. FDA approval earlier in 2026 was based on the phase III POTOMAC trial, which enrolled 1,018 patients and showed a statistically significant improvement in disease-free survival with durvalumab plus BCG compared with BCG alone, with a hazard ratio of 0.68.
Why it matters
- Patients / advocates: Delaying recurrence and cystectomy matters deeply, but patients need clear counselling on treatment duration and side effects.
- Clinicians: High-risk NMIBC is becoming a more systemic treatment conversation, not only an intravesical one.
- Hospitals / providers: Delivery depends on BCG availability, infusion capacity, immune-toxicity monitoring and follow-up discipline.
- Payers / HTA bodies: The value question must include cystectomy avoidance, recurrence delay, toxicity, clinic burden and BCG supply pressure.
BCG has been the backbone of high-risk non–muscle-invasive bladder cancer for decades. That backbone is now being asked to carry more weight.
The expanded POTOMAC analysis keeps durvalumab plus BCG in the centre of the debate. The regimen is not just trying to improve a scan or delay a minor event. It is trying to delay high-risk recurrence, progression and cystectomy. For patients, that is a serious outcome. A cystectomy is not a routine next step. It can alter urinary function, sexual function, body image, daily life and long-term wellbeing.
But the clinical result creates an implementation problem.
High-risk NMIBC already requires repeated cystoscopy, intravesical treatment, pathology review, risk stratification and patient adherence over time. Add a checkpoint inhibitor, and the pathway becomes even more demanding. Urology cannot do it alone. Medical oncology cannot do it in isolation. Nursing, scheduling, toxicity management and patient navigation become part of whether the approval actually works.
There is also a deeper access issue. BCG shortages have already exposed how fragile bladder-cancer treatment delivery can be. A new combination pathway will not fix that. It may even make variation more visible: centres with strong multidisciplinary teams move forward, while smaller services struggle with staffing, drug supply, monitoring and follow-up.
The real story is not that immunotherapy has entered earlier bladder-cancer care. The real story is whether health systems are ready for what that means.
